Efficacy of Inotuzumab Ozogamicin plus Ponatinib Followed by Allogeneic Stem Cell Transplantation in a Patient with Relapsed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
| Autor: | Vladimir Gerov, Merlin Efraim, Ilina Micheva, Stela Dimitrova |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Oncology
medicine.medical_specialty medicine.medical_treatment Case Report Hematopoietic stem cell transplantation 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Internal medicine hemic and lymphatic diseases medicine Diseases of the blood and blood-forming organs Inotuzumab ozogamicin Chemotherapy Philadelphia Chromosome Positive business.industry Ponatinib General Medicine Transplantation chemistry 030220 oncology & carcinogenesis RC633-647.5 Stem cell business Tyrosine kinase 030215 immunology medicine.drug |
| Zdroj: | Case Reports in Hematology Case Reports in Hematology, Vol 2021 (2021) |
| ISSN: | 2090-6579 2090-6560 |
| Popis: | Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL) is an aggressive disease with poor outcomes. Despite the incorporation of tyrosine kinase inhibitors (TKIs) in the therapeutic strategies, patients who relapse after chemotherapy plus TKI have poor overall survival (OS) and less chance to proceed to hematopoietic stem cell transplantation (HSCT) which remains the only curative approach. Therefore, new drugs, such as antibody-targeted therapies alone or in combination with TKIs, offer new therapeutic options for those patients. However, the combination of inotuzumab plus ponatinib has limited application. We present a case of a patient affected by Ph + ALL with T315I mutation successfully treated after early relapse with inotuzumab plus ponatinib, followed by allogeneic HSCT and ponatinib maintenance. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text